> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Dianthus Now Sees Its CIDP Trial Needing Fewer Than 200 Open-Label Patients, With $1.2 Billion Of Cash Lasting Into 2030
- URL: https://www.bullished.co/dianthus-now-sees-its-cidp-trial-needing-fewer-than-200-open-label-patients-with-1-2-709208fe/
- Published: 2026-11-04T23:28:36.000Z
- Updated: 2026-11-04T23:28:36.000Z
- Description: The biotech reported a $46.6 million third-quarter net loss and set Part A results for year-end 2027 and a multifocal motor neuropathy readout for December.
- Author: Matteo Parrino
- Tags: Earnings, DNTH, Industry: Healthcare

[Dianthus Therapeutics](https://www.bullished.co/tag/dnth/), a clinical-stage biotech developing treatments for severe autoimmune diseases, now projects that its Phase 3 CAPTIVATE trial of claseprubart in CIDP, a nerve disorder, will need [fewer than 200 participants](https://www.globenewswire.com/news-release/2026/11/04/3395769/0/en/dianthus-therapeutics-highlights-recent-business-achievements-and-reports-q3-2026-financial-results.html?ref=bullished.co) in its open-label first part, the company said Wednesday with third-quarter results. Cash of about $1.2 billion is projected to last into 2030.

## A shorter path to 128 responders

The open-label Part A has to produce [128 responders](https://www.globenewswire.com/news-release/2026/11/04/3395769/0/en/dianthus-therapeutics-highlights-recent-business-achievements-and-reports-q3-2026-financial-results.html?ref=bullished.co), who are then randomized into Part B, a placebo-controlled withdrawal study. The company called its under-200 projection conservative.

Part A top-line results are expected by year-end 2027 and Part B by year-end 2028\. An interim look at the first 40 participants to finish Part A showed a 75% response rate, above the 50% or greater target the company set based on precedent with this class of drug. Claseprubart was generally well tolerated, with no related serious infections or related serious adverse events, the company said.

The company cautioned that the interim analysis covers a limited number of patients and may not predict results for the rest of Part A or for Part B.

## Loss widens as spending climbs

Net loss for the quarter was [$46.6 million](https://www.sec.gov/Archives/edgar/data/0001690585/000169058526000039/dnth-ex99%5F1.htm?ref=bullished.co), or $0.81 per share, against $36.8 million, or $0.97 per share, a year earlier. Weighted shares rose to about 57.3 million from about 37.8 million.

Research spending rose to $45.6 million from $32.5 million, which the company tied to higher clinical costs and headcount for claseprubart's Phase 2 and Phase 3 work and to its two newer drug candidates. General and administrative expenses were $14.1 million, up from $8.2 million, on higher headcount. License revenue was $1.2 million.

Cash, equivalents and investments were about $1.2 billion at Sept. 30, which the company says funds operations into 2030.

## December readout in MMN

Claseprubart is an antibody designed to block the C1s complement protein, given as a self-administered injection under the skin. It is also in a Phase 3 trial in generalized myasthenia gravis, with results expected in the second half of 2028.

The Phase 2 MoMeNtum trial in multifocal motor neuropathy enrolled 46 patients, above its original target of 36, with top-line results due in December. A Phase 3 MMN trial is planned to begin in 2027\. CEO Marino Garcia said IVIg is the only approved treatment for MMN and that patient and physician dissatisfaction with it is "a meaningful opportunity" for claseprubart.

On its second candidate, DNTH212, preliminary healthy-volunteer data are expected in the first quarter of 2027, and a Dianthus-led multiple-ascending-dose study is planned for the second quarter of 2027.

The MoMeNtum results due in December are the next hard data point, ahead of CAPTIVATE Part A by year-end 2027.

Learn

- [Item 2.02: results of operations →](https://www.bullished.co/learn/8-k-items-explained/#item-202-results-of-operations)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — Dianthus Therapeutics, Inc. /DE/ (DNTH)](https://www.sec.gov/Archives/edgar/data/0001690585/000169058526000039/dnth-20261104.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit dnth-ex99\_1.htm — Dianthus Therapeutics, Inc. /DE/ 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001690585/000169058526000039/dnth-ex99%5F1.htm?ref=bullished.co) — SEC EDGAR
- [Dianthus Therapeutics Highlights Recent Business](https://www.globenewswire.com/news-release/2026/11/04/3395769/0/en/dianthus-therapeutics-highlights-recent-business-achievements-and-reports-q3-2026-financial-results.html?ref=bullished.co) — globenewswire.com

### More on Dianthus Therapeutics

- [Dianthus Sold $98.1 Million Of Stock In One Quarter, More Than The First Half Combined](https://www.bullished.co/dianthus-sold-98-1-million-of-stock-in-one-quarter-more-than-the-first-half-combined-8122690a/)
- [Vanguard Capital Management Reports 5.08% Passive Stake In Dianthus Therapeutics](https://www.bullished.co/vanguard-capital-management-reports-5-08-passive-stake-in-dianthus-therapeutics-a2a900f1/)

[All Dianthus Therapeutics (DNTH) coverage →](https://www.bullished.co/tag/dnth/)